(Q37951013)

25 August 2017

Exploiting nature's rich source of proteasome inhibitors as starting points in drug development (English)

1 reference

25 August 2017

Melissa Ann Gräwert

1

1 reference

PubMed ID

22039589

25 August 2017

Michael Groll

series ordinal

2

1 reference

PubMed ID

22039589

25 August 2017

language of work or name

English

0 references

publication date

31 October 2011

1 reference

25 August 2017

15

1 reference

based on heuristic

inferred from page(s)

published in

Chemical Communications

1 reference

25 August 2017

48

1 reference

25 August 2017

10

1 reference

25 August 2017

1364-1378

1 reference

Targeting cancer with small molecule kinase inhibitors

25 August 2017

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Proteasome inhibitors: recent advances and new perspectives in medicinal chemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Proteasome inhibitors as new anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Activation of the cell death program by inhibition of proteasome function

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Adaptive modification and flexibility of the proteasome system in response to proteasome inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

20S proteasome and its inhibitors: crystallographic knowledge for drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Joining the army of proteasome inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Proteasome inhibitors: Dozens of molecules and still counting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Inhibition of the ubiquitin-proteasome system by natural products for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Proteasome inhibition: a new therapeutic strategy to cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

The role of ubiquitin in NF-kappaB regulatory pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Marine actinomycetes: a new source of compounds against the human malaria parasite

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

The proteasome inhibitor MLN-273 blocks exoerythrocytic and erythrocytic development of Plasmodium parasites.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Structure of the Mycobacterium tuberculosis proteasome and mechanism of inhibition by a peptidyl boronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Inhibitors selective for mycobacterial versus human proteasomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

The 26S proteasome: assembly and function of a destructive machine

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Recognition and processing of ubiquitin-protein conjugates by the proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Diversity of degradation signals in the ubiquitin-proteasome system

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

The 26 S proteasome: from basic mechanisms to drug targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Structural features of the 26 S proteasome complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

The structure of the mammalian 20S proteasome at 2.75 A resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

The catalytic sites of 20S proteasomes and their role in subunit maturation: a mutational and crystallographic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Eukaryotic 20S proteasome catalytic subunit propeptides prevent active site inactivation by N-terminal acetylation and promote particle assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Evidence that pituitary cation-sensitive neutral endopeptidase is a multicatalytic protease complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

PRE3, highly homologous to the human major histocompatibility complex-linked LMP2 (RING12) gene, codes for a yeast proteasome subunit necessary for the peptidylglutamyl-peptide hydrolyzing activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Evidence for the presence of five distinct proteolytic components in the pituitary multicatalytic proteinase complex. Properties of two components cleaving bonds on the carboxyl side of branched chain and small neutral amino acids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Regulation of CD8+ T cell development by thymus-specific proteasomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Structural and serological similarity of MHC-linked LMP and proteasome (multicatalytic proteinase) complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Antigen processing by the proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Structure of 20S proteasome from yeast at 2.4 A resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

A giant protease with potential to substitute for some functions of the proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Structural Analysis of Spiro β-Lactone Proteasome Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Crystal structures of Salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of beta-lactone ring opening and a mechanism for irreversible binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Total synthesis of natural tert-alkylamino hydroxy carboxylic acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Total synthesis of lactacystin and salinosporamide A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Structural basis for activation and inhibition of the secreted chlamydia protease CPAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Widespread and persistent populations of a major new marine actinomycete taxon in ocean sediments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Structure-activity relationship studies of salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

New cytotoxic salinosporamides from the marine Actinomycete Salinispora tropica

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Discovery and development of the anticancer agent salinosporamide A (NPI-0052).

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Salinosporamide natural products: Potent 20 S proteasome inhibitors as promising cancer chemotherapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Salinosporamides D-J from the marine actinomycete Salinispora tropica, bromosalinosporamide, and thioester derivatives are potent inhibitors of the 20S proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Antiprotealide is a natural product.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

An efficient, stereocontrolled synthesis of a potent omuralide-salinosporin hybrid for selective proteasome inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Snapshots of the fluorosalinosporamide/20S complex offer mechanistic insights for fine tuning proteasome inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Enantioselective total syntheses of belactosin A, belactosin C, and its homoanalogue

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Inhibitor-binding mode of homobelactosin C to proteasomes: new insights into class I MHC ligand generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Total synthesis of the potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Proteasome inhibition by the natural products epoxomicin and dihydroeponemycin: insights into specificity and potency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Towards subunit-specific proteasome inhibitors: synthesis and evaluation of peptide alpha',beta'-epoxyketones.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Lack of proteasome active site allostery as revealed by subunit-specific inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Elucidation of the α-keto-aldehyde binding mechanism: a lead structure motif for proteasome inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Nature of pharmacophore influences active site specificity of proteasome inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047).

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Proteasome inhibition by fellutamide B induces nerve growth factor synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Bivalency as a principle for proteasome inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Crystallographic structure studies of an IgG molecule and an Fc fragment

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Crystal structure of the 20 S proteasome:TMC-95A complex: a non-covalent proteasome inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

A concise, total synthesis of the TMC-95A/B proteasome inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

The total synthesis of proteasome inhibitors TMC-95A and TMC-95B: discovery of a new method to generate cis-propenyl amides

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

The core structure of TMC-95A is a promising lead for reversible proteasome inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Binding mode of TMC-95A analogues to eukaryotic 20S proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Probing structural determinants distal to the site of hydrolysis that control substrate specificity of the 20S proteasome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

20S proteasome inhibition: designing noncovalent linear peptide mimics of the natural product TMC-95A

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S β5-subunit

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Optimization of a series of dipeptides with a P3 threonine residue as non-covalent inhibitors of the chymotrypsin-like activity of the human 20S proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

FoxM1 is a general target for proteasome inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Proteasome inhibitory activity of thiazole antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

A plant pathogen virulence factor inhibits the eukaryotic proteasome by a novel mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Syringolin A selectively labels the 20 S proteasome in murine EL4 and wild-type and bortezomib-adapted leukaemic cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Pseudomonas syringae virulence factor syringolin A counteracts stomatal immunity by proteasome inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Biosynthesis of the proteasome inhibitor syringolin A: the ureido group joining two amino acids originates from bicarbonate

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Protein polyubiquitination plays a role in basal host resistance of barley.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Functional analysis of genes involved in the synthesis of syringolin A by Pseudomonas syringae pv. syringae B301 D-R.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

A bacterial virulence protein suppresses host innate immunity to cause plant disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Syringolin A, a new plant elicitor from the phytopathogenic bacterium Pseudomonas syringae pv. syringae, inhibits the proliferation of neuroblastoma and ovarian cancer cells and induces apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Complementary whole-genome technologies reveal the cellular response to proteasome inhibition by PS-341

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Inhibition of proteasome activity induces concerted expression of proteasome genes and de novo formation of Mammalian proteasomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Identification of genes involved in the biosynthesis of the cytotoxic compound glidobactin from a soil bacterium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Synthetic and structural studies on syringolin A and B reveal critical determinants of selectivity and potency of proteasome inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Scytonemides A and B, cyclic peptides with 20S proteasome inhibitory activity from the cultured cyanobacterium Scytonema hofmanii

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Feasibility of xeno-transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Xenotransplantation of solid organs in the pig-to-primate model

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Long-term follow-up of patients with type 1 diabetes transplanted with neonatal pig islets

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Proteasome inhibition for antibody-mediated rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Bortezomib in kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Proteasome inhibitors: poisons and remedies

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Global analysis of proteasomal substrate specificity using positional-scanning libraries of covalent inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Cinnabaramides A−G: Analogues of Lactacystin and Salinosporamide from a Terrestrial Streptomycete

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC1CC15273D

Belactosin A, a novel antitumor antibiotic acting on cyclin/CDK mediated cell cycle regulation, produced by Streptomyces sp

21 January 2018

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.53.81

Tyropeptins A and B, New Proteasome Inhibitors Produced by Kitasatospora sp. MK993-dF2. I. Taxonomy, Isolation, Physico-chemical Properties and Biological Activities.

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.54.997

TMC-95A, B, C, and D, novel proteasome inhibitors produced by Apiospora montagnei Sacc. TC 1093. Taxonomy, production, isolation, and biological activities.

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.53.105

TMC-89A and B, new proteasome inhibitors from streptomyces sp. TC 1087

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.53.967

TMC-86A, B and TMC-96, new proteasome inhibitors from Streptomyces sp. TC 1084 and Saccharothrix sp. TC 1094. I. Taxonomy, fermentation, isolation, and biological activities.

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.52.1069

Structure of lactacystin, a new microbial metabolite which induces differentiation of neuroblastoma cells

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.44.117

Eponemycin, a new antibiotic active against B16 melanoma. I. Production, isolation, structure and biological activity

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.43.8

Glidobactins A, B and C, new antitumor antibiotics. I. Production, isolation, chemical properties and biological activity.

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.41.1331

Identifiers

DOI

10.1039/C1CC15273D

1 reference

25 August 2017

1 reference

PubMed ID

22039589